Constipation - Pipeline Review, H2 2012

Global Markets Direct, September 2012, Pages: 98

Constipation – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Constipation - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Constipation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Constipation. Constipation - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Constipation.
- A review of the Constipation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Constipation pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Constipation.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Constipation pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

2
List of Tables 6
List of Figures 7
Introduction 8
REPORT COVERAGE 8
Constipation Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Constipation 10
Constipation Therapeutics under Development by Companies 12
Constipation Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 17
Comparative Analysis 17
Mid Clinical Stage Products 18
Comparative Analysis 18
Early Clinical Stage Products 19
Comparative Analysis 19
Pre-Clinical Stage Products 20
Comparative Analysis 20
Constipation Therapeutics – Products under Development by Companies 21
Constipation Therapeutics – Products under Investigation by Universities/Institutes 22
Companies Involved in Constipation Therapeutics Development 23
Dainippon Sumitomo Pharma Co., Ltd. 23
Dong-A Pharmaceutical Co., Ltd. 24
Shire Plc 25
ARYx Therapeutics 26
Yuhan Corporation 27
Theravance, Inc. 28
Sucampo Pharmaceuticals, Inc. 29
Ironwood Pharmaceuticals, Inc. 30
Synergy Pharmaceuticals, Inc. 31
Braintree Laboratories, Inc. 32
Ferring Pharmaceuticals, Inc. 33
Ardelyx, Inc. 34
MicroDose Therapeutx, Inc. 35
Beech Tree Labs, Inc. 36
Constipation – Therapeutics Assessment 37
Assessment by Monotherapy Products 37
Assessment by Combination Products 38
Assessment by Route of Administration 39
Assessment by Molecule Type 41
Drug Profiles 43
naronapride - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
prucalopride - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
linaclotide - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
linaclotide - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
lubiprostone - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
MDT-006 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
velusetrag - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
plecanatide - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
mosapride citrate - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
chenodeoxycholic acid sodium salt - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
YKP-10811 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
pyridostigmine bromide - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
elobixibat - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Neostigmine + Glycopyrrolate - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
methylnaltrexone bromide - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
methylnaltrexone bromide - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
escitalopram oxalate - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Drug For Chronic Constipation - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
DA-6886 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
BLI-801 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
RDX-5791 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
DSP-6952 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
lactulose - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
YH-12852 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Constipation Therapeutics – Drug Profile Updates 73
Constipation Therapeutics – Discontinued Products 85
Constipation Therapeutics - Dormant Products 86
Constipation – Product Development Milestones 87
Featured News & Press Releases 87
Aug 30, 2012: Ironwood And Forest Labs Announce FDA Approval Of Linzess For Treatment Of Irritable Bowel Syndrome With Constipation And Chronic Idiopathic Constipation 87
Aug 14, 2012: Synergy Pharma Completes Screening And Planned Enrollment In Phase IIb/III Study In Chronic Idiopathic Constipation Patients 89
Jul 31, 2012: Synergy Pharma To Present Scientific Posters On Plecanatide At Upcoming Gastroenterology Society Meetings 89
Jul 06, 2012: R-Tech Ueno Announces Result Of Arbitration Against Takeda Pharma 90
Jul 06, 2012: Sucampo Pharma Announces Arbitration Decision In Its Dispute With Takeda 90
Jul 05, 2012: Sucampo And Abbott Announce Approval For AMITIZA In Japan 91
May 20, 2012: Sucampo Presents Data From Two Phase III Studies Of AMITIZA At Digestive Disease Week 2012 92
May 14, 2012: Ironwood Pharma And Forest To Present 17 Linaclotide-Related Abstracts At Digestive Disease Week 2012 93
Apr 23, 2012: Ironwood And Forest Announce FDA's Extension Of Review Period For Linaclotide To September 2012 95
Apr 18, 2012: Sucampo And Clinigen Announce Named Patient Program For EU, Iceland And Norway To Provide Access To AMITIZA For Chronic Idiopathic Constipation Patients 95
Appendix 97
Methodology 97
Coverage 97
Secondary Research 97
Primary Research 97
Expert Panel Validation 97
Contact Us 98
Disclaimer 98

List of Tables
Number of Products Under Development for Constipation, H2 2012 10
Products under Development for Constipation – Comparative Analysis, H2 2012 11
Number of Products under Development by Companies, H2 2012 13
Number of Products under Development by Companies, H2 2012 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H2 2012 16
Comparative Analysis by Late Stage Development, H2 2012 17
Comparative Analysis by Mid Clinical Stage Development, H2 2012 18
Comparative Analysis by Early Clinical Stage Development, H2 2012 19
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 20
Products under Development by Companies, H2 2012 21
Products under Investigation by Universities/Institutes, H2 2012 22
Dainippon Sumitomo Pharma Co., Ltd., H2 2012 23
Dong-A Pharmaceutical Co., Ltd., H2 2012 24
Shire Plc, H2 2012 25
ARYx Therapeutics, H2 2012 26
Yuhan Corporation, H2 2012 27
Theravance, Inc., H2 2012 28
Sucampo Pharmaceuticals, Inc., H2 2012 29
Ironwood Pharmaceuticals, Inc., H2 2012 30
Synergy Pharmaceuticals, Inc., H2 2012 31
Braintree Laboratories, Inc., H2 2012 32
Ferring Pharmaceuticals, Inc., H2 2012 33
Ardelyx, Inc., H2 2012 34
MicroDose Therapeutx, Inc., H2 2012 35
Beech Tree Labs, Inc., H2 2012 36
Assessment by Monotherapy Products, H2 2012 37
Assessment by Combination Products, H2 2012 38
Assessment by Stage and Route of Administration, H2 2012 40
Assessment by Stage and Molecule Type, H2 2012 42
Constipation Therapeutics – Drug Profile Updates 73
Constipation Therapeutics – Discontinued Products 85
Constipation Therapeutics – Dormant Products 86

List of Figures
Number of Products under Development for Constipation, H2 2012 10
Products under Development for Constipation – Comparative Analysis, H2 2012 11
Products under Development by Companies, H2 2012 12
Products under Investigation by Universities/Institutes, H2 2012 15
Late Stage Products, H2 2012 17
Mid Clinical Stage Products, H2 2012 18
Early Clinical Stage Products, H2 2012 19
Pre-Clinical Stage Products, H2 2012 20
Assessment by Monotherapy Products, H2 2012 37
Assessment by Combination Products, H2 2012 38
Assessment by Route of Administration, H2 2012 39
Assessment by Stage and Route of Administration, H2 2012 40
Assessment by Molecule Type, H2 2012 41
Assessment by Stage and Molecule Type, H2 2012 42

Customers who bought this item also bought

• Drug Addiction – Pipeline Review, H1 2013
• Substance (Drug) Abuse – Pipeline Review, H1 2013
• Bone Disorders – Pipeline Review, H1 2013
• Nausea – Pipeline Review, H1 2013
• Smoking Cessation – Pipeline Review, H1 2013
• Brain Tumor – Pipeline Review, H1 2013
• Pandemic Influenza – Pipeline Review, H1 2013
• Skin And Skin Structure Infections (SSSI) – Pipeline Review, H1 2013
• Ebola Viral Infections – Pipeline Review, H1 2013
• Premature Ejaculation – Pipeline Review, H1 2013